Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718213 | 0.99 | MCHR1 (0.44) | MCHR1TLR8HRH3KCNH2CYP3A4 | |
| SCHEMBL2721201 | 0.99 | MCHR1 (0.44) | MCHR1TLR8HRH3KCNH2CYP3A4 | |
| SCHEMBL2720234 | 0.99 | MCHR1 (0.44) | MCHR1TLR8HRH3KCNH2CYP3A4 | |
| SCHEMBL2717625 | 0.96 | MCHR1 (0.46) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2717711 | 0.92 | MCHR1 (0.47) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2717763 | 0.84 | HRH3 (0.52) | HRH3KCNH2CYP3A4CYP2C9RAB9A | |
| SCHEMBL2717431 | 0.84 | MCHR1 (0.41) | MCHR1HRH3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2720561 | 0.83 | HRH3 (0.51) | HRH3KCNH2CYP3A4CYP2C9RAB9A | |
| SCHEMBL2719574 | 0.83 | HRH3 (0.51) | HRH3KCNH2CYP3A4CYP2C9RAB9A | |
| SCHEMBL2721397 | 0.83 | HRH3 (0.51) | HRH3KCNH2CYP3A4CYP2C9RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1995245-B1 | METHOD FOR PRODUCING EPOXY COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20090054669-A1 | Process For Producing Epoxy Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1995245-A1 | METHOD FOR PRODUCING EPOXY COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054669-A1 | Process For Producing Epoxy Compound | RER1, AR, CYP1A1 | MCHR1 621/4885TLR8 3905/4885HRH3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.